Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30,095 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Kumar S, Çalışkan DM, Janowski J, Faist A, Conrad BCG, Lange J, Ludwig S, Brunotte L. Kumar S, et al. Front Immunol. 2021 Oct 1;12:752227. doi: 10.3389/fimmu.2021.752227. eCollection 2021. Front Immunol. 2021. PMID: 34659259 Free PMC article. Review.
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.
Faist A, Schloer S, Mecate-Zambrano A, Janowski J, Schreiber A, Boergeling Y, Conrad BCG, Kumar S, Toebben L, Schughart K, Baumgardt M, Kessler M, Hoenzke K, Hocke A, Trautmann M, Hartmann W, Kato H, Rescher U, Christersson A, Kuehn J, Mellmann A, Wolff T, Kuempers P, Rovas A, Wiewrodt R, Wiebe K, Barth P, Ludwig S, Brunotte L. Faist A, et al. Among authors: kumar s. Antiviral Res. 2023 Jan;209:105475. doi: 10.1016/j.antiviral.2022.105475. Epub 2022 Nov 21. Antiviral Res. 2023. PMID: 36423831 Free PMC article.
Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J, Meister TL, Todt D, Bracht T, Schork K, Billaud JN, Elsner C, Heinen N, Karakoese Z, Haid S, Kumar S, Brunotte L, Eisenacher M, Di Y, Lew J, Falzarano D, Chen J, Yuan Z, Pietschmann T, Wiegmann B, Uebner H, Taube C, Le-Trilling VTK, Trilling M, Krawczyk A, Ludwig S, Sitek B, Steinmann E, Dittmer U, Lavender KJ, Sutter K, Pfaender S. Schuhenn J, et al. Among authors: kumar s. Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):e2111600119. doi: 10.1073/pnas.2111600119. Proc Natl Acad Sci U S A. 2022. PMID: 35131898 Free PMC article.
Benign breast tumors may arise on different immunological backgrounds.
Torland LA, Lai X, Kumar S, Riis MH, Geisler J, Lüders T, Tekpli X, Kristensen V, Sahlberg K, Tahiri A. Torland LA, et al. Among authors: kumar s. Mol Oncol. 2024 May 16. doi: 10.1002/1878-0261.13655. Online ahead of print. Mol Oncol. 2024. PMID: 38757377
Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
Kirthiga Devi SS, Singh S, Joga R, Patil SY, Meghana Devi V, Chetan Dushantrao S, Dwivedi F, Kumar G, Kumar Jindal D, Singh C, Dhamija I, Kumar S. Kirthiga Devi SS, et al. Among authors: kumar s. Eur J Pharm Biopharm. 2024 May 14:114323. doi: 10.1016/j.ejpb.2024.114323. Online ahead of print. Eur J Pharm Biopharm. 2024. PMID: 38754524 Review.
30,095 results
You have reached the last available page of results. Please see the User Guide for more information.